Pfizer expects 8 blockbuster cancer drugs to ... Ensacove has its own ongoing phase 3 in the adjuvant setting, albeit only among Chinese patients. It’s estimated that about 5% of NSCLC cases ...

As spikes in a respiratory virus and images of overwhelmed intensive care units emerge, there is a worrying echo of the early days of Covid. Zoë Beaty asks if Beijing is downplaying what is happening ...

Zai Lab (NASDAQ:ZLAB) announced Wednesday it would seek marketing approval for its cervical cancer therapy Tivdak (tisotumab ...

NEW YORK, Jan. 14 (Xinhua) -- Pfizer Inc., the American multinational pharmaceutical and biotechnology corporation, is offering around 700 million shares in Haleon Plc, representing a roughly 7.7 ...

An outbreak of the flu-like virus in China is causing concern, but experts say a Covid-like pandemic is unlikely.

As China continues to monitor an increase in cases of human metapneumovirus (HMPV), here's what you need to know about the ...

China Resources Pharmaceutical Group (CR Pharmaceutical ... The drug, developed by US pharmaceutical giant Pfizer for certain types of advanced breast cancer, was approved for sale in 2015.

We’ve got another full slate of news items from the conference, including the growing anxiety and excitement about Chinese drug candidates, a pitch for the new Editas, and a dispatch from one of ...

Pfizer’s PFE stock has risen 5.6% in the past month. This was due to the company’s encouraging guidance for 2025 issued in mid-December 2025. Pfizer also maintained its previously issued ...